Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers

The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by researchers at The University of Texas MD Anderson Cancer Center.

Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Thursday 19 November →